NeuroOne Medical (NMTC) Announces Proposed Public Offering of Common Stock

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.

All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, the Company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the proposed offering.

You May Also Be Interested In

• Nuvectis Pharma (NVCT) files $200M mixed shelf
• Boeing names Ryan Shedd as new SVP and controller
• Aptevo Therapeutics files prospectus for resale of 6.4M shares